ARRIVENT BIOPHARMA INC. - COMMON STOCK

27.45

22-十一月-24 15:44:58

15 分钟延时

股票

+0.86

+3.23%

今日范围

25.65 - 27.68

ISIN

N/A

来源

NASDAQ

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

14 11月 2024 07:00:00 条件 Nasdaq GlobeNewswire
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

09 9月 2024 11:05:00 条件 Nasdaq GlobeNewswire
ArriVent BioPharma Reports Second Quarter 2024 Financial Results

14 8月 2024 15:01:00 条件 Nasdaq GlobeNewswire
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

12 8月 2024 07:00:00 条件 Nasdaq GlobeNewswire
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

05 6月 2024 06:00:00 条件 Nasdaq GlobeNewswire
ArriVent Appoints John Hohneker, M.D., to its Board of Directors

16 5月 2024 15:05:00 条件 Nasdaq GlobeNewswire

<<
<
1
>

我同意 NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie 政策, 隐私政策 and 条款与条件.